PDS Biotechnology Net Worth
PDS Biotechnology Net Worth Breakdown | PDSB |
PDS Biotechnology Net Worth Analysis
PDS Biotechnology's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including PDS Biotechnology's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of PDS Biotechnology's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform PDS Biotechnology's net worth analysis. One common approach is to calculate PDS Biotechnology's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares PDS Biotechnology's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing PDS Biotechnology's net worth. This approach calculates the present value of PDS Biotechnology's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of PDS Biotechnology's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate PDS Biotechnology's net worth. This involves comparing PDS Biotechnology's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into PDS Biotechnology's net worth relative to its peers.
Enterprise Value |
|
To determine if PDS Biotechnology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding PDS Biotechnology's net worth research are outlined below:
| PDS Biotechnology generated a negative expected return over the last 90 days | |
| PDS Biotechnology has high historical volatility and very poor performance | |
| PDS Biotechnology has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (42.94 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| PDS Biotechnology Corp currently holds about 52.98 M in cash with (33.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.86. | |
| PDS Biotechnology has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Open Networking Edge Summit 2025 Heads to London, Alongside KubeCon CloudNativeCon Europe, March 31 - April 1, 2025 |
PDS Biotechnology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in PDS Biotechnology Corp. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to PDS Biotechnology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know PDS Biotechnology's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as PDS Biotechnology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading PDS Biotechnology Corp backward and forwards among themselves. PDS Biotechnology's institutional investor refers to the entity that pools money to purchase PDS Biotechnology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Citadel Advisors Llc | 2024-09-30 | 115 K | Jane Street Group Llc | 2024-06-30 | 114 K | Northern Trust Corp | 2024-09-30 | 92.8 K | Commonwealth Equity Services Inc | 2024-06-30 | 78.9 K | Amussen, Hunsaker & Associates Incorporated | 2024-06-30 | 75 K | Xtx Topco Ltd | 2024-09-30 | 67.2 K | Ubs Group Ag | 2024-06-30 | 60 K | Bank Of America Corp | 2024-06-30 | 45 K | Squarepoint Ops Llc | 2024-06-30 | 41 K | Vanguard Group Inc | 2024-09-30 | 1.5 M | Blackrock Inc | 2024-06-30 | 487 K |
Follow PDS Biotechnology's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 80.43 M.Market Cap |
|
Project PDS Biotechnology's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.72) | (0.76) | |
| Return On Capital Employed | (0.94) | (0.99) | |
| Return On Assets | (0.72) | (0.76) | |
| Return On Equity | (1.64) | (1.56) |
When accessing PDS Biotechnology's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures PDS Biotechnology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of PDS Biotechnology's profitability and make more informed investment decisions.
Please note, the presentation of PDS Biotechnology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, PDS Biotechnology's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of PDS Biotechnology's management manipulating its earnings.
Evaluate PDS Biotechnology's management efficiency
PDS Biotechnology Corp has return on total asset (ROA) of (0.3995) % which means that it has lost $0.3995 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.284) %, meaning that it created substantial loss on money invested by shareholders. PDS Biotechnology's management efficiency ratios could be used to measure how well PDS Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. As of November 28, 2024, Return On Tangible Assets is expected to decline to -0.76. In addition to that, Return On Capital Employed is expected to decline to -0.99. At present, PDS Biotechnology's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 63.4 M, whereas Non Current Assets Total are forecasted to decline to about 318.3 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.84 | 0.80 | |
| Tangible Book Value Per Share | 0.84 | 0.80 | |
| Enterprise Value Over EBITDA | (3.02) | (3.17) | |
| Price Book Value Ratio | 5.89 | 6.18 | |
| Enterprise Value Multiple | (3.02) | (3.17) | |
| Price Fair Value | 5.89 | 6.18 | |
| Enterprise Value | 294.4 M | 309.2 M |
Leadership at PDS Biotechnology emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Return On Equity (1.28) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific PDS Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on PDS Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases PDS Biotechnology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
PDS Biotechnology Corporate Filings
8K | 14th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
PDS Biotechnology Earnings per Share Projection vs Actual
PDS Biotechnology Corporate Management
| Joe Dervan | VP Development | Profile | |
| Lars MBA | Chief Officer | Profile | |
| Deanne Randolph | Head Relations | Profile | |
| Gregory Conn | Chief Scientific Officer | Profile | |
| Spencer JD | Senior Counsel | Profile | |
| Nathalie Riebel | VP Operations | Profile | |
| Janetta Trochimiuk | Controller | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PDS Biotechnology Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PDS Biotechnology. If investors know PDS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PDS Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.19) | Return On Assets (0.40) | Return On Equity (1.28) |
The market value of PDS Biotechnology Corp is measured differently than its book value, which is the value of PDS that is recorded on the company's balance sheet. Investors also form their own opinion of PDS Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is PDS Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PDS Biotechnology's market value can be influenced by many factors that don't directly affect PDS Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PDS Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if PDS Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PDS Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.